Cargando…
Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice
BACKGROUND: Histone deacetylase (HDAC) inhibitors, developed as promising anti-tumor drugs, exhibit their anti-inflammatory properties due to their effects on reduction of inflammatory cytokines. OBJECTIVE: To investigate the protective effect of butyrate, a HDAC inhibitor, on lipopolysaccharide (LP...
Autores principales: | Ni, Yun-Feng, Wang, Jian, Yan, Xiao-Long, Tian, Feng, Zhao, Jin-Bo, Wang, Yun-Jie, Jiang, Tao |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848144/ https://www.ncbi.nlm.nih.gov/pubmed/20302656 http://dx.doi.org/10.1186/1465-9921-11-33 |
Ejemplares similares
-
Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012) -
Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
por: Chen, Yiming, et al.
Publicado: (2021) -
Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice
por: Li, Xiaohua, et al.
Publicado: (2019) -
The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging
por: Walsh, Michael E., et al.
Publicado: (2015) -
Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)